What is the recommended antimicrobial therapy for Enterobacter cloacae infection?

Antimicrobial Therapy for Enterobacter cloacae Infection

For carbapenem-resistant Enterobacter cloacae (CRE), use ceftazidime-avibactam 2.5 g IV every 8 hours as first-line therapy, or alternatively meropenem-vaborbactam 4 g IV every 8 hours or imipenem-cilastatin-relebactam 1.25 g IV every 6 hours. For carbapenem-susceptible strains, carbapenems (meropenem, imipenem, or doripenem) remain the preferred agents 1.

Treatment Algorithm Based on Resistance Pattern

Carbapenem-Resistant E. cloacae (CRE)

Bloodstream Infections:

• First choice: Ceftazidime-avibactam 2.5 g IV every 8 hours infused over 3 hours 1
• Alternative options:
  • Meropenem-vaborbactam 4 g IV every 8 hours infused over 3 hours 1
  • Imipenem-cilastatin-relebactam 1.25 g IV every 6 hours 1
• If new beta-lactam/beta-lactamase inhibitors unavailable: Polymyxin-based combination therapy (colistin loading dose 300 mg CMS, maintenance 300-360 mg CMS divided in two doses) combined with tigecycline, carbapenem, or aminoglycosides based on susceptibility testing 1

Complicated Urinary Tract Infections:

• Ceftazidime-avibactam 2.5 g IV every 8 hours 1
• Meropenem-vaborbactam 4 g IV every 8 hours 1
• Plazomicin 15 mg/kg IV every 12 hours 1
• Single-dose aminoglycoside for simple cystitis 1

Intra-abdominal Infections:

• Ceftazidime-avibactam 2.5 g IV every 8 hours PLUS metronidazole 1
• Tigecycline 100 mg IV loading dose, then 50 mg IV every 12 hours 1
• Eravacycline 1 mg/kg infused over 60 minutes IV every 12 hours 1
• Polymyxin-based combination therapy if above unavailable 1

Carbapenem-Susceptible E. cloacae

Severe Infections (APACHE II ≥15 or critically ill):

• Meropenem, imipenem, or doripenem as monotherapy 2
• Piperacillin-tazobactam 2
• Ceftazidime or cefepime PLUS metronidazole (for intra-abdominal sources) 2

Mild to Moderate Infections:

• Ceftriaxone or cefotaxime PLUS metronidazole (for intra-abdominal sources) 3, 2
• Piperacillin-tazobactam 2

Critical Considerations for E. cloacae

Resistance Development During Therapy

E. cloacae possesses chromosomally-mediated AmpC beta-lactamase that can be induced during therapy, causing resistance to develop even to previously susceptible antibiotics 4. This is particularly problematic with third-generation cephalosporins and requires:

• Monitoring blood cultures during therapy to ensure adequacy 4
• Avoiding cephalosporins as monotherapy for serious infections
• Preferring carbapenems for severe infections when susceptible

Combination Therapy Rationale

For multidrug-resistant E. cloacae, combination therapy demonstrates superior outcomes:

• Imipenem-colistin combination shows synergistic activity both in vitro and in vivo models, with complete bacterial killing at 1-2× MIC 5, 6
• High-dose imipenem (4× MIC) alone or combined with colistin effectively inhibits growth for >48 hours 6
• Colistin monotherapy, even at high doses, results in bacterial regrowth after 4 hours and is not recommended 6

Metallo-Beta-Lactamase (MBL) Producers

If E. cloacae produces MBL enzymes:

• Aztreonam-avibactam is the preferred agent when available 7
• Alternative: Ceftazidime-avibactam PLUS aztreonam combination 8, 7
• This combination is specifically endorsed by IDSA and ESCMID guidelines 7

Site-Specific Recommendations

Endocarditis (rare but serious):

• Beta-lactam antibiotic PLUS aminoglycoside combination 4
• Careful monitoring of blood cultures essential due to potential resistance development 4
• Valvular surgery indicated for medical management failure 4

Neonatal Sepsis:

• Piperacillin (or piperacillin-tazobactam) PLUS gentamicin or amikacin 9
• Early recognition critical as presentation is nonspecific 9

Monitoring and Adjustments

• Therapeutic drug monitoring (TDM) should be performed for polymyxins and aminoglycosides when used 10
• Avoid combining nephrotoxic agents (aminoglycosides, polymyxins) when possible 10
• Adjust therapy based on susceptibility testing results once available 1
• For polymyxin-carbapenem combinations, consider if meropenem MIC ≤8 mg/L with extended 3-hour infusion 10

Common Pitfalls to Avoid

1. Do not use third-generation cephalosporins as monotherapy for serious E. cloacae infections due to AmpC induction risk
2. Do not use colistin monotherapy - always combine with another active agent 1, 6
3. Do not use tigecycline monotherapy for pneumonia - associated with higher treatment failure rates 1
4. Do not delay appropriate therapy - inappropriate empirical therapy associated with mortality rates up to 86% 1
5. Do not assume species-level identification is accurate - laboratory methods frequently misidentify ECC species, potentially delaying outbreak recognition 11